RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency

Halvas, EK., Aldrovandi, GM., Balfe, P., Beck, IA., Boltz, VF., Coffin, JM., Frenkel, LM., Hazelwood, JD., Johnson, VA., Kearney, M., Kovacs, A., Kuritzkes, DR., Metzner, KJ., Nissley, DV., Nowicki, M., Palmer, S., Ziermann, R., Zhao, RY., Jennings, CL., ... Mellors, JW. (2006). Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. Journal of Clinical Microbiology, 44(7), 2612-2614. https://doi.org/10.1128/JCM.00449-06

Abstract

We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy

10.1128/JCM.00449-06

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.